Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $350.36

Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $357.17.

UTHR has been the subject of several recent research reports. Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Oppenheimer upped their price objective on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. TD Cowen upped their price objective on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 269 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total value of $1,153,620.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,658.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. The disclosure for this sale can be found here. Insiders sold a total of 111,252 shares of company stock valued at $36,939,427 in the last quarter. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares in the last quarter. LSV Asset Management lifted its holdings in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after acquiring an additional 22,683 shares in the last quarter. Pacer Advisors Inc. lifted its stake in United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares in the last quarter. Finally, Norges Bank bought a new position in United Therapeutics during the 4th quarter valued at $100,519,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 0.2 %

UTHR stock opened at $358.53 on Friday. The stock has a market capitalization of $15.95 billion, a P/E ratio of 16.95, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $366.08. The firm has a 50-day moving average price of $342.08 and a 200-day moving average price of $295.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same period in the prior year, the company earned $5.24 EPS. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics will post 24.84 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.